Skip to main
OLMA
OLMA logo

Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals (OLMA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Olema Pharmaceuticals presents a promising outlook due to the efficacy of its drug candidate palazestrant (OP-1250), which has demonstrated a median progression-free survival (mPFS) of 7.2 months in the broader population and similar results in both ESR1 mutant and wild-type patients. The company’s planned Phase 3 trials for the combination of palazestrant with ribociclib reflect confidence in achieving potentially differentiated efficacy, with preliminary data indicating a median PFS exceeding 13 months, which may position it as best-in-class among current therapies. Given these encouraging results and the strategic focus on women's cancers, Olema's advancements indicate substantial potential for growth and success in the biopharmaceutical market.

Bears say

Olema Pharmaceuticals faces several substantial risks that contribute to a negative outlook, including potential safety signals from its clinical and preclinical programs. The efficacy of its drug candidates, such as OP-1250 and OP-3136, may also fall short of expectations, compounded by the threat of increased competition from other treatment options in both development and the market. Additionally, significant financing requirements present a challenge, with estimates suggesting a cash runway extending only into 2027, alongside a projected need for approximately $600 million by 2040, which could strain the company’s financial stability.

Olema Pharmaceuticals (OLMA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Olema Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Olema Pharmaceuticals (OLMA) Forecast

Analysts have given Olema Pharmaceuticals (OLMA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Olema Pharmaceuticals (OLMA) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Olema Pharmaceuticals (OLMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.